Dietary fructose as a metabolic risk factor

Am J Physiol Cell Physiol. 2022 Sep 1;323(3):C847-C856. doi: 10.1152/ajpcell.00439.2021. Epub 2022 Jul 25.

Abstract

Over the past decades, the role of the intestinal microbiota in metabolic diseases has come forward. In this regard, both composition and function of our intestinal microbiota is highly variable and influenced by multiple factors, of which diet is one of the major elements. Between 1970 and 1990, diet composition has changed and consumption of dietary sugars has increased, of which fructose intake rose by more than 10-fold. This increased intake of sugars and fructose is considered as one of the major risk factors in the developments of obesity and several metabolic disturbances. In this review, we describe the association of dietary fructose intake with insulin resistance, nonalcoholic fatty liver disease (NAFLD) and lipid metabolism. Moreover, we will focus on the potential causality of this altered gut microbiota using fecal transplantation studies in human metabolic disease and whether fecal microbial transplant can reverse this phenotype.

Keywords: cardiometabolic disease; fructose; gut microbiota; insulin resistance; metabolites.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diet / adverse effects
  • Fructose* / adverse effects
  • Fructose* / metabolism
  • Humans
  • Liver / metabolism
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Risk Factors

Substances

  • Fructose